Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 7 de 7
Filter
Add more filters










Database
Language
Publication year range
1.
Am J Physiol Heart Circ Physiol ; 301(2): H488-96, 2011 Aug.
Article in English | MEDLINE | ID: mdl-21572004

ABSTRACT

Frequency potentiation of contractile function is a major mechanism of the increase in myocardial performance during exercise. In heart failure (HF), this positive force-frequency relation is impaired, and the abnormal left ventricular (LV)-arterial coupling is exacerbated by tachycardia. A myofilament Ca(2+) sensitizer, levosimendan, has been shown to improve exercise tolerance in HF. This may be due to its beneficial actions on the force-frequency relation and LV-arterial coupling (end-systolic elastance/arterial elastance, E(ES)/E(A)). We assessed the effects of therapeutic doses of levosimendan on the force-frequency relation and E(ES)/E(A) in nine conscious dogs after pacing-induced HF using pressure-volume analysis. Before HF, pacing tachycardia increased E(ES), shortened τ, and did not impair E(ES)/E(A) and mechanical efficiency (stroke work/pressure-volume area, SW/PVA). In contrast, after HF, pacing at 140, 160, 180, and 200 beat/min (bpm) produced smaller a increase of E(ES) or less shortening of τ, whereas E(ES)/E(A) (from 0.56 at baseline to 0.42 at 200 bpm) and SW/PVA (from 0.52 at baseline to 0.43 at 200 bpm) progressively decreased. With levosimendan, basal E(ES) increased 27% (6.2 mmHg/ml), τ decreased 11% (40.8 ms), E(ES)/E(A) increased 34% (0.75), and SW/PVA improved by 15% (0.60). During tachycardia, E(ES) further increased by 23%, 37%, 68%, and 89%; τ decreased by 9%, 12%, 15%, and 17%; and E(ES)/E(A) was augmented by 11%, 16%, 31%, and 33%, incrementally, with pacing rate. SW/PVA was improved (0.61 to 0.64). In conclusion, in HF, treatment with levosimendan restores the normal positive LV systolic and diastolic force-frequency relation and prevents tachycardia-induced adverse effect on LV-arterial coupling and mechanical efficiency.


Subject(s)
Cardiotonic Agents/pharmacology , Excitation Contraction Coupling/drug effects , Heart Failure/drug therapy , Hydrazones/pharmacology , Myocardial Contraction/drug effects , Pyridazines/pharmacology , Ventricular Dysfunction, Left/drug therapy , Ventricular Function, Left/drug effects , Analysis of Variance , Animals , Cardiac Pacing, Artificial , Disease Models, Animal , Dogs , Heart Failure/etiology , Heart Failure/physiopathology , Heart Rate/drug effects , Male , Simendan , Stroke Volume/drug effects , Tachycardia/drug therapy , Tachycardia/etiology , Tachycardia/physiopathology , Time Factors , Ventricular Dysfunction, Left/etiology , Ventricular Dysfunction, Left/physiopathology , Ventricular Pressure/drug effects
2.
Diabetes Res Clin Pract ; 83(2): 233-40, 2009 Feb.
Article in English | MEDLINE | ID: mdl-19118913

ABSTRACT

OBJECTIVE: To assess the efficacy and tolerability of vildagliptin (10, 25 or 50mg bid) in Japanese patients with type 2 diabetes mellitus (T2DM). METHODS: This 12-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study was performed in 291 patients. The primary assessment was change from baseline to endpoint in HbA1c. RESULTS: Baseline HbA1c averaged 7.4%, and the between-treatment difference (vildagliptin-placebo) in the HbA1c adjusted mean change was -0.8%, -1.0% and -1.2% with vildagliptin 10, 25 and 50mg bid, respectively (p<0.001). Relative to baseline, body weight did not change significantly in vildagliptin groups. There was no increase in incidence of adverse events in the vildagliptin groups (62.0%, 62.5% and 61.8%, 10, 25 and 50mg bid, respectively) compared to placebo (73.6%). No deaths or drug-related serious adverse events were reported. Seven hypoglycemic events were observed (four events (n=3), two events (n=2), and one event (n=1) in the vildagliptin 10 and 50mg bid, and placebo, respectively) and none of them were severe or dose related. CONCLUSION: Vildagliptin 50mg bid was considered to be the most effective and well-tolerated dose, and therefore can be considered the recommended clinical dose for Japanese patients with T2DM.


Subject(s)
Adamantane/analogs & derivatives , Blood Glucose/drug effects , Diabetes Mellitus, Type 2/drug therapy , Nitriles/administration & dosage , Pyrrolidines/administration & dosage , Adamantane/administration & dosage , Adamantane/adverse effects , Adult , Aged , Blood Glucose/metabolism , Diabetes Mellitus, Type 2/blood , Diabetes Mellitus, Type 2/metabolism , Dose-Response Relationship, Drug , Double-Blind Method , Female , Glycated Hemoglobin/analysis , Glycated Hemoglobin/drug effects , Humans , Hypoglycemic Agents/administration & dosage , Hypoglycemic Agents/adverse effects , Japan , Male , Middle Aged , Nitriles/adverse effects , Placebos , Pyrrolidines/adverse effects , Treatment Outcome , Vildagliptin , Young Adult
3.
Biochem Biophys Res Commun ; 343(4): 1060-6, 2006 May 19.
Article in English | MEDLINE | ID: mdl-16579967

ABSTRACT

Cardiac stress consistently activates c-Jun NH(2)-terminal kinase (JNK) pathways, however the role of different members of the JNK family is unclear. In this study, we applied pressure overload (TAC) in mice with selective deletion of the three JNK genes (Jnk1(-/-), Jnk2(-/-), and Jnk3(-/-)). Following TAC, all three JNK knockout mouse lines developed cardiac hypertrophy similar to wild-type mice (WT), but only JNK1(-/-) mice displayed a significant reduction in fractional shortening after 3 and 7 days of pressure overload, associated with a significant increase in terminal deoxynucleotidyl transferase-mediated dUTP nick end-labeling staining and marked inflammatory infiltrate. After the acute deterioration stage, JNK1(-/-) mice underwent a slow recovery followed by a steady progression of cardiac dysfunction, becoming indistinguishable from WT after 12 weeks of TAC. These data suggest that JNK1 plays a protective role in response to pressure overload, preventing the early deterioration in cardiac function following an acute increase in afterload.


Subject(s)
Cardiomegaly/physiopathology , Mitogen-Activated Protein Kinase 8/physiology , Myocardium/pathology , Animals , Aorta/pathology , Apoptosis , Blood Pressure , Cardiomegaly/enzymology , Constriction, Pathologic , Female , In Situ Nick-End Labeling , Male , Mice , Mice, Knockout , Mitogen-Activated Protein Kinase 10/genetics , Mitogen-Activated Protein Kinase 10/physiology , Mitogen-Activated Protein Kinase 8/genetics , Mitogen-Activated Protein Kinase 9/genetics , Mitogen-Activated Protein Kinase 9/physiology , Myocardium/enzymology , Phenotype
4.
Methods Mol Med ; 112: 353-62, 2005.
Article in English | MEDLINE | ID: mdl-16010029

ABSTRACT

Beta-adrenergic receptor signaling, desensitization, and downregualtion are fundamental mechanisms that contribute to both normal and altered myocardial function. The development of pharmacological and biochemical assays has provided the ability to measure alterations both in adrenergic receptor density and the subsequent coupling of adrenergic receptors downstream effectors, namely, adenylyl cyclase. Furthermore, transthoracic echocardiography of the murine heart has provided insight into changes in cardiac physiology that accompany altered adrenergic receptor signaling. The protocols described within this chapter provide the means to quantify beta-adrenergic density, measure adenylyl cyclase activity, and evaluate cardiac hypertrophy to better understand the mechanisms responsible for cardiac hypertrophy and heart failure.


Subject(s)
Cardiomegaly/metabolism , Receptors, Adrenergic, beta/metabolism , Signal Transduction , Adenylyl Cyclases/analysis , Adenylyl Cyclases/metabolism , Animals , Cardiomegaly/physiopathology , Cell Membrane/metabolism , Echocardiography , Hemodynamics , Ligands , Mice , Myocardium/cytology , Radioligand Assay , Receptors, Adrenergic, beta/analysis
5.
Circulation ; 111(5): 591-7, 2005 Feb 08.
Article in English | MEDLINE | ID: mdl-15668342

ABSTRACT

BACKGROUND: Heart failure is characterized by abnormalities in beta-adrenergic receptor (betaAR) signaling, including increased level of myocardial betaAR kinase 1 (betaARK1). Our previous studies have shown that inhibition of betaARK1 with the use of the Gbetagamma sequestering peptide of betaARK1 (betaARKct) can prevent cardiac dysfunction in models of heart failure. Because inhibition of betaARK activity is pivotal for amelioration of cardiac dysfunction, we investigated whether the level of betaARK1 inhibition correlates with the degree of heart failure. METHODS AND RESULTS: Transgenic (TG) mice with varying degrees of cardiac-specific expression of betaARKct peptide underwent transverse aortic constriction (TAC) for 12 weeks. Cardiac function was assessed by serial echocardiography in conscious mice, and the level of myocardial betaARKct protein was quantified at termination of the study. TG mice showed a positive linear relationship between the level of betaARKct protein expression and fractional shortening at 12 weeks after TAC. TG mice with low betaARKct expression developed severe heart failure, whereas mice with high betaARKct expression showed significantly less cardiac deterioration than wild-type (WT) mice. Importantly, mice with a high level of betaARKct expression had preserved isoproterenol-stimulated adenylyl cyclase activity and normal betaAR densities in the cardiac membranes. In contrast, mice with low expression of the transgene had marked abnormalities in betaAR function, similar to the WT mice. CONCLUSIONS: These data show that the level of betaARK1 inhibition determines the degree to which cardiac function can be preserved in response to pressure overload and has important therapeutic implications when betaARK1 inhibition is considered as a molecular target.


Subject(s)
Cardiac Output, Low/etiology , Cyclic AMP-Dependent Protein Kinases/antagonists & inhibitors , Myocardium/enzymology , Peptides/genetics , Recombinant Proteins/genetics , Adenylyl Cyclases/metabolism , Animals , Cardiac Output, Low/diagnostic imaging , Cardiac Output, Low/enzymology , Constriction , Cyclic AMP-Dependent Protein Kinases/metabolism , Heart/physiopathology , Mice , Mice, Transgenic , Peptides/metabolism , Pressure , Recombinant Proteins/metabolism , Signal Transduction , Ultrasonography , beta-Adrenergic Receptor Kinases
6.
Am J Physiol Heart Circ Physiol ; 288(2): H914-22, 2005 Feb.
Article in English | MEDLINE | ID: mdl-15486041

ABSTRACT

The new myofilament Ca2+ sensitizer levosimendan (LSM) is a positive inotropic and vasodilatory agent. Its beneficial effects have been demonstrated at rest in congestive heart failure (CHF). However, its effect during exercise (Ex) in CHF is unknown. We assessed the effects of LSM on left ventricular (LV) dynamics at rest and during Ex in eight conscious, instrumented dogs with pacing-induced CHF. After CHF, with dogs at rest, LSM decreased arterial elastance (Ea) and increased LV contractile performance as assessed by the slope of LV pressure-volume (P-V) relation. LSM caused a >60% increase in the peak rate of mitral flow (dV/dtmax) due to decreases in minimal LV pressure and the time constant of LV relaxation (tau). LV arterial coupling, quantified as the ratio of end-systolic elastance (Ees) to Ea, was increased from 0.47 to 0.85%. LV mechanical efficiency, determined as the ratio of stroke work to total P-V area, was improved from 0.54 +/- 0.09 to 0.61 +/- 0.07. These beneficial effects persisted during Ex after CHF. Compared with CHF Ex dogs, treatment with LSM prevented Ex-induced abnormal increases in mean left atrial pressure and end-diastolic pressure and decreased Ees/Ea. With LSM treatment during CHF Ex, the early diastolic portion of the LV P-V loop was shifted downward with decreased minimal LV pressure and tau values and a further augmented dV/dtmax. Ees/Ea improved, and mechanical efficiency further increased from 0.61 +/- 0.07 to 0.67 +/- 0.07, which was close to the value reached during normal Ex. After CHF, LSM produced arterial vasodilatation; improved LV relaxation and diastolic filling; increased contractility, LV arterial coupling, and mechanical efficiency; and normalized the response to Ex.


Subject(s)
Cardiotonic Agents/pharmacology , Heart Failure/drug therapy , Hydrazones/pharmacology , Physical Exertion/physiology , Pyridazines/pharmacology , Ventricular Function, Left/drug effects , Animals , Diastole/drug effects , Dogs , Heart Failure/physiopathology , Pacemaker, Artificial , Rest/physiology , Simendan , Systole/drug effects
7.
J Clin Invest ; 112(7): 1067-79, 2003 Oct.
Article in English | MEDLINE | ID: mdl-14523044

ABSTRACT

beta-Adrenergic receptor (betaAR) downregulation and desensitization are hallmarks of the failing heart. However, whether abnormalities in betaAR function are mechanistically linked to the cause of heart failure is not known. We hypothesized that downregulation of cardiac betaARs can be prevented through inhibition of PI3K activity within the receptor complex, because PI3K is necessary for betaAR internalization. Here we show that in genetically modified mice, disrupting the recruitment of PI3K to agonist-activated betaARs in vivo prevents receptor downregulation in response to chronic catecholamine administration and ameliorates the development of heart failure with pressure overload. Disruption of PI3K/betaAR colocalization is required to preserve betaAR signaling, since deletion of a single PI3K isoform (PI3Kgamma knockout) is insufficient to prevent the recruitment of other PI3K isoforms and subsequent betaAR downregulation with catecholamine stress. These data demonstrate a specific role for receptor-localized PI3K in the regulation of betaAR turnover and show that abnormalities in betaAR function are associated with the development of heart failure. Thus, a strategy that blocks the membrane translocation of PI3K and leads to the inhibition of betaAR-localized PI3K activity represents a novel therapeutic approach to restore normal betaAR signaling and preserve cardiac function in the pressure overloaded failing heart.


Subject(s)
Cyclic AMP-Dependent Protein Kinases/physiology , Enzyme Inhibitors/pharmacology , Heart Failure/drug therapy , Phosphoinositide-3 Kinase Inhibitors , Receptors, Adrenergic, beta/physiology , Animals , Cardiomegaly/etiology , Enzyme Inhibitors/therapeutic use , Heart Failure/etiology , Heart Failure/physiopathology , Isoproterenol/pharmacology , Mice , Mice, Knockout , Phosphatidylinositol 3-Kinases/physiology , Protein Transport , Receptors, Adrenergic, beta/analysis , beta-Adrenergic Receptor Kinases
SELECTION OF CITATIONS
SEARCH DETAIL
...